- 1 Title
- 2 Phenotypic spectrum of *FAM47E-SHROOM3* haplotype composition in a general population
 3 sample
- 4

5 Authors

- 6 Dariush Ghasemi-Semeskandeh^{1,2,3}, Eva König¹, Luisa Foco¹, Nikola Dordevic¹, Martin Gögele¹,
- Johannes Rainer¹, Markus Ralser⁴, Dianne Acoba^{5,6}, Francisco S. Domingues¹, Dorien J. M.
- 8 Peters², Peter P. Pramstaller¹, Cristian Pattaro¹
- 9
- 10 1. Institute for Biomedicine, Eurac Research, Bolzano, Italy.
- 11 2. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
- 12 3. Health Data Science Centre, Human Technopole, V.le Rita Levi-Montalcini, 1, Milan 20157,
- 13 Italy.
- 14 4. Institute of Biochemistry, Charité Universitätsmedizin Berlin, Berlin, Germany.
- 15 5. Clinical Renal, Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM),
- 16 BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- 17 6. Institut Necker Enfants-Malades (INEM), Institut National de la Santé et de la Recherche
- 18 Médicale (INSERM) U1151, Université Paris Cité, Paris, France
- 19
- 20 **Corresponding authors**
- 21 Dariush Ghasemi-Semeskandeh
- 22 Human Technopole, Health Data Science Centre
- 23 V.le Rita Levi-Montalcini, 1, Milan 20157, Italy.
- 24 Email: ghasemi.dariush@yahoo.com
- 25
- 26 Cristian Pattaro
- 27 Eurac Research, Institute for Biomedicine
- 28 Via Volta 21, I-39100 Bozen/Bolzano
- 29 T +39 0471 055 527
- 30 Email: cristian.pattaro@eurac.edu

31 Abstract

Genome-wide association studies identified a locus on chromosome 4q21.1, spanning the *FAM47E*, *STBD1*, *CCDC158*, and *SHROOM3* genes, as associated with kidney function markers. Functional studies implicated *SHROOM3*, encoding an actin-binding protein involved in cell shaping, into podocyte barrier damage. Despite the locus was also found associated with electrolytes, hematological and cardiovascular traits, systematic explorations of functional variants across all the genes in the locus are lacking.

We reconstructed haplotypes covering the whole locus on 12,834 participants to the Cooperative Health Research in South Tyrol (CHRIS) study, using genotypes imputed on a wholeexome sequencing reference panel of a subsample of 3,422 participants. Haplotypes included 146 exonic and intronic variants over the four genes and were tested for association with 73 serum, urine and anthropometric traits, 172 serum metabolite and 148 plasma protein concentrations using linear regression models.

We identified 11 haplotypes with 2% to 24% frequency. Compared to the most common 44 haplotype, most haplotypes were associated with higher levels of the creatinine-based estimated 45 glomerular filtration rate and lower serum magnesium levels. The second most common 46 haplotype (12% frequency) was additionally associated with lower dodecanoyl-, hydroxyvaleryl-47 and tiglyl-carnitine serum concentrations. A haplotype of 4% frequency was also associated with 48 49 lower red blood cell count, hemoglobin, and hematocrit levels. A haplotype of 2% frequency was 50 associated with serum glutamine and putrescine concentrations. Cluster analysis revealed 51 distinct groups of traits and of haplotypes.

52 The *FAM47E-SHROOM3* locus exhibits haplotype variability that corresponds to marked 53 pleiotropic effects, implicating the existence of population subgroups with distinct biomarker 54 profiles.

55

56 Keywords

SHROOM3; FAM47E; haplotype; kidney; population; Cooperative Health Research In South
Tyrol (CHRIS) study

59 Introduction

A genetic locus on chromosome 4q21.1 has been prominently associated with multiple markers of kidney function, including the estimated glomerular filtration rate based on serum creatinine (eGFRcrea) or cystatin C¹⁻⁶ and albuminuria.⁷ The genetic associations lie within two recombination hotspots that embed a high linkage disequilibrium (LD) region spanning four genes: Family With Sequence Similarity 47 Member E (*FAM47E*); Starch Binding Domain 1 (*STBD1*); Coiled-Coil Domain Containing 158 (*CCDC158*); and the first exons of the Shroom Family Member 3 (*SHROOM3*).

67 Follow-up functional studies have mainly focused on SHROOM3, which encodes a PDZdomain-containing protein regulating cell shape, neural tube formation⁸ and epithelial 68 morphogenesis. SHROOM3 is involved in maintaining normal podocyte structure,⁹ particularly 69 through binding of the TCF7L2 transcription factor.¹⁰ *Shroom3* modulates the actomyosin network 70 which maintains podocyte architecture.¹¹ Variants altering the SHROOM3 actin-binding domain 71 may cause podocyte effacement and glomerular filtration barrier impairment.⁹ Furthermore, 72 73 Shroom3 knockdown causes albuminuria and podocyte foot process effacement in mice as well 74 as defective lamellipodia formation in podocytes and disrupted slit diaphragms in rat glomerular epithelial cells.¹² SHROOM3 alterations may also implicate craniofacial alterations^{13,14} and cardiac 75 76 defects.¹⁵ Less attention has been dedicated to the other genes in the locus.

Beyond kidney function, genetic variants at this locus are associated with diverse phenotypes, including platelets,¹⁶ hemoglobin (HGB),¹⁶ serum magnesium,¹⁷ and Parkinson's disease.¹⁸ The alleles associated with lower eGFRcrea are also associated with lower urine albumin-to-creatinine ratio (UACR),⁷ despite glomerular *Shroom3* knockdown should induce albuminuria.¹⁹

Altogether, this evidence suggests that, while *SHROOM3* is a promising molecular target for chronic kidney disease (CKD) prevention,¹⁰ the genetic variability of the whole *FAM47E-SHROOM3* locus warrants more extensive investigations to comprehensively characterize the corresponding phenotypic spectrum. This may also clarify whether the previously reported, apparent mediatory role of serum magnesium on the association between eGFRcrea and the locus²⁰ reflects real biological mechanisms or rather the joint genetic regulation of the two traits.

To investigate the presence of distinct genetic profiles involving diverse phenotypic manifestations, we conducted a haplotype analysis of genetic variants in the *FAM47E-SHROOM3* region imputed from a whole-exome sequencing (WES) panel, in an Alpine population-based

study. Notoriously, haplotype analysis does not illuminate causal mechanisms but instead, it is a
population genetic tool to explore a locus's heterogeneity in population. Reconstructed haplotypes
were tested for association against 73 clinical traits, 172 target serum metabolites, and 148
plasma protein markers.

95

96 Methods

97 Study sample

We analyzed data from the Cooperative Health Research in South Tyrol (CHRIS) study, conducted in South Tyrol, Italy, between 2011 and 2018.²¹ Following overnight fasting, 13,393 participants underwent early morning blood drawing, urine collection, anthropometric measurements, and blood pressure measurements.²² Health and lifestyle information was gathered through computer-based standardized questionnaire-based interviews. The analysis overview is given through a flowchart in **Figure 1A**.

104

105 Genomics

All DNA samples were genotyped on the Illumina HumanOmniExpressExome or Omni2.5Exome arrays and called with GenomeStudio v2010.3 with default settings on GRCh37, lifted to GRCh38 via CrossMap v0.6.5. Variants with GenTrain score <0.6, cluster separation score <0.4, or call rate <80% were considered technical failures and discarded. Variants present on both arrays were submitted to further quality control (QC) and removed if monomorphic or not in Hardy-Weinberg equilibrium (P<10⁻⁶). Samples with <0.98 call rate were removed.

Samples from a subset of 3840 participants underwent WES (xGen® Exome Research Panel v1.0; McDonnell Genome Institute, Washington University). Data processing, read alignment and QC were conducted as detailed previously.^{23,24} We retained 3422 samples with a post-QC mean target coverage of 68.4X.

WES data were used as a population-specific reference panel for genotype imputation onto the whole CHRIS sample as reported previously.²³ Based on 181 WES samples excluded from the reference panel for testing purposes, we observed excellent imputation quality between imputed genotypes and sequenced hard-calls (median Pearson's correlation=0.99).²³

120

121 Clinical, metabolomics, and proteomics traits

Information on genotype data and clinical traits was available for 12,834 participants. Clinical traits included blood and urinary markers, diastolic and systolic blood pressure (SBP), and body mass index (BMI; **Suppl. Tab. 1**). eGFRcrea was estimated with the race-free CKD-EPI equation using the R package 'nephro' v1.3.0.²⁵ Laboratory assay effects²⁶ were addressed through quantile normalization as detailed previously.²⁰ Missing values were imputed to the median.

Targeted metabolomics analysis involved a subset of 7252 participants, whose serum samples were analyzed with the AbsoluteIDQ p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria). Normalization and QC of the 188 measured metabolites are described elsewhere.²⁷ To increase sample homogeneity, pregnant women and individuals of non-European descent were excluded. Metabolites with >20% missing data were excluded. Missing values were imputed to the median, otherwise. QC left 172 high-quality metabolites available on 6642 samples (**Suppl. Tab. 1**).

On a subset of 4087 participants we measured 148 plasma proteins, using massspectrometry-based scanning SWATH.²⁸ Data generation and processing was described elsewhere.²⁹ After merging with the genetic data, 3535 participants remained for the analysis (**Suppl. Tab. 1**).

138

139 Haplotype association analysis

The region of interest on chromosome 4 was bounded by two recombination peaks at positions 140 76,251,700 and 76,516,500, encompassing 152 WES-based imputed variants spanning 141 FAM47E, FAM47E–STBD1, CCDC158 and SHROOM3 (Figure 1B). Retaining 146 variants with 142 143 minor allele frequency>0.0001 and with imputation quality index Rsg>0.3 (median Rsg=0.87; Suppl. Tab. 2), haplotype reconstruction and regression analysis was conducted using the 144 haplo.glm function of the R package 'haplo.stats' v1.8.9, exploiting an expectation-maximization 145 146 algorithm for haplotype inference³⁰ (Supplementary Methods). Alleles were aligned on the major allele as the reference. Haplotypes with <0.02 frequency were collapsed into a rare-haplotype 147 category. We fitted linear association models on the inverse normal transformation of each trait, 148 metabolite, and protein, including haplotypes as predictors and adjusting for age, sex, and the 149 first 10 genetic principal components (PCs), estimated on the genotyped autosomal variants, to 150 151 control for population structure.

152 Among the 73 considered clinical traits, 18 traits have been previously reported with 153 genome-wide significant associations with variants in the locus (GWAS Catalog interrogation at 154 https://www.ebi.ac.uk/gwas/ on 23-Aug-2023; Figure 2A). These traits were tested for association with the haplotypes at the significance level α =0.05, considering the strong prior 155 evidence of association. For the remaining clinical traits, the 172 metabolites, and the 148 156 proteins, we set α at 0.05/50=0.001, 0.05/88=5.68×10⁻⁴ and 0.05/113=4.42×10⁻⁴, respectively, 157 where 50, 88, and 113 were the number of independent PCs necessary to explain 95% of each 158 159 dataset's variability (analyses conducted with the prcomp function in the R package 'stats' v4.3.0).

160

161 Cluster analysis

We performed hierarchical clustering of the z-scores obtained from the significant associations between haplotypes and traits and metabolites. Similarity was based on the Euclidean distance and clustering implemented based on the 'Ward D2' approach via *hclust* in the 'stats' R package. We applied the Silhouette method to the non-scaled z-scores to determine the optimal number of clusters for haplotypes and traits, using the *fviz_nbclust and hcut* functions in the R package 'factoextra' v1.0.7, allowing a maximum of 8 and 18 clusters, respectively.

168

169 Variant annotation

Genetic variants were annotated with the Ensembl Variant Effect Predictor v100.2 170 (http://www.ensembl.org/info/docs/tools/vep/index.html), 171 predicting the most severe consequences with the 'split-vep' plugin. LD between WES-imputed variants selected for 172 haplotype analysis and previously reported common variants associated with the traits of interest 173 was assessed through the D' statistic, which reflects the underlying haplotype diversity,³¹ 174 estimated using PLINK v1.9.32 175

We queried the haplotype-tagging variants in the European ancestry datasets of the GTEx Consortium v8 database (<u>https://gtexportal.org/home/</u>; 10-Aug-2023) across 48 tissues (n=65 to 573 samples per tissue) and in NephQTL2³³ (6-Feb-2024), to test association with the expression of the four genes in the locus (P<5×10⁻⁸), and across 4502 whole blood protein GWAS summary results available in ³⁴ to identify protein quantitative trait loci (pQTLs) at P<5×10⁻⁸ (n=35,559; <u>https://decode.com/summarydata</u>; 11-Oct-2023).

182

183 Results

184 Characterization of the FAM47E-SHROOM3 genomic variants

The 12,834 participants (54.3% females) had a median age of 46 years and median eGFRcrea level of 92.9 ml/min/1.73m²; 3.6% had eGFRcrea<60 ml/min/1.73m² and 5.9% had UACR>30 mg/g (**Table 1**). The sample appeared as an extract of the general population, with no particularly prevalent clinical aspects (**Suppl. Tab. 1**).

Within the locus we identified 146 WES-imputed variants. They were largely intronic, but also included missense variants as well as synonymous, stop-gain, splicing, and other types of functional variants (**Figure 2B, Suppl. Tab. 2**). The variants were all in strong-to-perfect LD with common variants previously associated with common traits (**Figure 2C**). GWAS catalog interrogation showed the marked locus' pleiotropic nature (**Figure 2A**; **Suppl. Fig. 1**).

Haplotype reconstruction identified 11 haplotypes (H1 to H11) with \geq 2% frequency (**Suppl. Fig. 2**), which were uniquely tagged by 27 of the 146 variants (**Figure 2D**): rs3733251, rs3733250, and rs1036788 are missense variants in *FAM47E* and rs80162610 is a splice variant at *CCDC158*. Similar haplotype distributions were observed in the metabolomics and proteomics subsamples (**Figure 2D**).

The 27 haplotype-tagging variants were not associated with *SHROOM3* expression (Figure 3A; Suppl. Tab. 3). rs2289514, rs1876538, rs3733253, rs964051, and the missense variant rs3733250 at *FAM47E* were associated with *FAM47E* expression across most tissues. The remaining variants were associated with the expression of at least one among *FAM47E*, *CCDC158*, and *STBD1* in different tissues. No variant was a kidney-specific eQTL for the four investigated genes in the GTEx. NephQTL2 database interrogation did not identify any genomewide significant eQTLs in the glomerular and tubulointerstitial tissues (**Suppl. Tab. 4**).

206 The proteins encoded by the four genes in the locus were not included in the CHRIS or in the deCODE plasma proteomic datasets [36]. However, in the latter, we observed associations 207 208 with proteins (Figure 3B) whose encoding genes are also located on chromosome 4q21.1, 209 immediately to the left of the recombination peak next to FAM47E: the ADP-ribosyltransferase 3 (NAR3) encoded by ART3, the N-acylethanolamine acid amidase (NAAA) encoded by the 210 homonymous gene, and the C-X-C motif chemokine ligand 11 (CXCL11; see Figure 1B for 211 localization). Twenty-two of the 27 haplotype-tagging variants were associated with at least one 212 213 of those three proteins. Specifically, FAM47E missense variant rs3733251 was associated with 214 all three proteins and with the C-X-C motif chemokine ligand 6 (CXCL6), whose encoding gene

seats on the contiguous 4q13 cytoband. Other variants associated with all three adjacent proteins
were rs6532316 in *FAM47E* and rs72657825 and rs6857452 in *CCDC158*. NAAA was associated
with most variants, including the *SHROOM3* intronic variant rs10006043. Variant rs6812193 in *FAM47E* was additionally associated with sphingomyelin phosphodiesterase 1 (SMPD1),
hyaluronidase 1 (HYAL1), and the activating transcription factor 6 beta (ATF6B), whose encoding
genes are in different chromosomes.

221

222 Haplotype association analyses and hierarchical clustering

223 Haplotypes were first tested for association with the 18 traits for which there was a previously reported association with single variants at the locus (Table 2, Suppl. Tab. 5). 224 Compared to the reference haplotype, haplotype H1 was associated with higher SBP and lower 225 226 levels of mean corpuscular hemoglobin (MCH), HGB and magnesium. H4 was associated with 227 lower serum magnesium and creatinine levels as well as higher eGFRcrea, UACR, and BMI levels. H5 was associated with lower alkaline phosphatase (ALP). H6, the second most common 228 haplotype (frequency=11.6%), was associated with lower serum creatinine (P=4.92×10⁻⁶) and 229 230 platelet count (PLT) and higher eGFRcrea (P=0.004). H7 was associated with lower serum magnesium and creatinine (P=0.044). H8 was associated with lower serum creatinine (P=0.001) 231 as well as higher eGFRcrea ($P=2.72\times10^{-4}$). UACR (P=0.003) and SBP (P=0.019). H9 was 232 233 associated with lower HGB, red blood cell count (RBC), hematocrit, magnesium, serum creatinine 234 and higher eGFRcrea. H10 was associated with lower magnesium levels. For the 55 remaining 235 traits without prior evidence of association with variants in the locus, we identified an additional 236 association between H4 and lower basophil levels ($P=4.18\times10^{-4}$), after multiple testing control.

Haplotypes were also associated with serum metabolites (**Table 2**; **Suppl. Tab. 6**): H1 with higher phosphatidylcholine C42:0 (P=4.39×10⁻⁴); H3 with lower histidine (P=4.28×10⁻⁴); H10 with lower glutamine (P=1.08×10⁻⁴) and putrescine (P=2.26×10⁻⁴). H6 was associated with lower dodecenoylcarnitine (P=2.82×10⁻⁴), hydroxyvalerylcarnitine (P=1.31×10⁻⁴), and tiglylcarnitine (P=4.48×10⁻⁴) concentrations. **Suppl. Fig. 3** outlines all associations between haplotypes, clinical traits, and metabolites. After multiple testing control, no significant association between haplotypes and the 148 targeted plasma proteins was identified (**Suppl. Tab. 7**).

For haplotypes associated with both clinical traits and metabolites, we repeated the haplotype-metabolite association tests adjusting for the clinical traits (**Table 3**): haplotype effects on metabolites remained generally unchanged, indicating independent effects, except for H6

effect on carnitines that was attenuated by serum creatinine adjustment, potentially indicatingcommon regulatory mechanisms.

249

250 Cluster analyses of significant trait-haplotype associations

251 Hierarchical clustering of the haplotype effects on the significantly associated 13 clinical 252 traits and 7 metabolites, identified 6 clusters of traits, according to the Silhouette method (Figure 253 4: Suppl. Fig. 4). Cluster 1 included red blood cells (HGB, hematocrit, RBC, MCH) and immune 254 traits (basophils). Cluster 2 grouped together putrescine, glutamine, and histidine. Cluster 3 included serum creatinine and magnesium. Cluster 4 involved a combination of clinical traits (PLT, 255 BMI) and metabolites (dodecenoylcarnitine). Cluster 5 included carnitines hydroxyvalerylcarnitine 256 and tiglylcarnitine. Cluster 6 included traits associated with kidney function (eGFRcrea, UACR), 257 blood pressure (SBP), liver transaminases (ALP) and phosphatidylcholine C42:0. When 258 259 clustering by haplotype, the Silhouette method identified two clusters, one grouping H1, H3, H6, H9 and H10 and a second one including H2, H4, H7, and H8. Altogether, the identified cluster 260 structure suggests the existence of distinct genetic and correspondingly phenotypic 261 characteristics at FAM47E-SHROOM3, where individuals with specific haplotypes present 262 specific phenotypic and metabolic signatures. 263

264

265 Discussion

Our comprehensive investigation of 11 haplotypes derived from 146 WES-imputed variants and 266 267 evaluated across 393 clinical traits, metabolites, and proteins, highlights haplotypic profiles at FAM47E-SHROOM3 associated with distinct phenotype manifestations. We extend previous 268 studies on the role of SHROOM3 on kidney function regulation,¹⁰ by additionally showing that 269 270 haplotypes spanning SHROOM3 include missense variants at FAM47E, which seems the most relevant gene in the haplotype after SHROOM3, raising the possibility of complex interactions. 271 272 Given its function of promoting histone methylation, FAM47E might epigenetically regulate SHROOM3 transcription. STBD1 is involved in glycogen metabolism and protein is absent in the 273 kidney, while CCDC158 is strictly testis specific. 274

The diffuse association of most haplotypes with both lower serum magnesium and higher eGFRcrea suggests that the previously observed mediation between the two traits²⁰ more likely reflects their joint regulation by genes in the locus. Association of haplotypes H4 and H8 with lower serum creatinine and higher UACR and eGFRcrea at the same time, is compatible with

279 reduced muscle mass causing lower circulating creatinine and thus higher eGFRcrea and lower 280 urinary creatinine excretion increasing UACR. Nevertheless, H8 association with higher SBP is 281 consistent with the increased risk of incident hypertension in albuminuric individuals.³⁵ Similar 282 results were observed for H4, despite non-significant association with higher SBP. Given H4 and 283 H8 do not share any alleles at the 27 tagging variants, their similar characteristics might reflect 284 LD with functional variants outside the reconstructed haplotypes.

285 Haplotype H6 was associated with lower serum creatinine and lower acylcarnitines 286 dodecenoylcarnitine, hydroxyvalerylcarnitine, and tiglylcarnitine concentrations. Acylcarnitines 287 transport fatty acids from the cytosol into the mitochondria to produce energy through betaoxidation.³⁶ They are freely filtered by the kidney and excreted in the urine.³⁷ As kidney function 288 decreases, serum acylcarnitines should increase.³⁸ This was observed in CKD patients exhibiting 289 high serum dodecenoylcarnitine, hydroxyvalerylcarnitine and tiglylcarnitine concentrations linked 290 to low eGFR.³⁷ This aligns with our findings, suggesting that H6 might confer nephroprotection 291 292 through carnitine reduction. Alternatively, H6 might be in LD with SHROOM3 alleles conferring 293 sustained structural integrity of the podocytes, resulting in better filtration capacity lowering both 294 creatinine levels and free acylcarnitines concentrations.

Haplotypes H9 and H1 were associated with lower levels of red blood cell traits. The kidney produces erythropoietin, which is key to red blood cell production.³⁹ Lower kidney function could lead to less or defective red blood cells but connection with H9 is difficult as the haplotype is associated at the same time with higher eGFRcrea.

H3 carriers had lower histidine concentrations and statistically non-significant lower 299 300 putrescine and glutamine concentrations. Similarly, H10 carriers showed significantly lower putrescine and glutamine and non-significant lower histidine. Histidine is an anti-inflammatory and 301 antioxidant factor. In CKD patients, low histidine concentrations are associated with energy 302 wasting, inflammation, oxidative stress, and mortality,40 and histidine supplementation is 303 beneficial.⁴¹ Kidney filtration plays a role in putrescine concentrations:⁴² dialyzed patients have 304 lower serum putrescine than non-dialyzed patients.⁴³ A study on diabetic mice has postulated that 305 putrescine from ornithine catabolism activates mTOR signaling,⁴⁴ leading to podocyte loss by 306 regulating autophagy, oxidative stress, and endoplasmic reticulum stress.⁴⁵ Under glycolytic 307 blockage, podocytes use amino acids as oxidative phosphorylation substrates to produce 308 energy.⁴⁴ Less putrescine in H10 carriers might reflect well-functioning podocytes and glomeruli 309 following proper SHROOM3 function. However, such protective effect contradicts the 310 simultaneous negative association between H3 and histidine and between H10 and glutamine. 311

312 Glutamine, the most abundant amino acid in humans, synthesized by most tissues and involved in numerous metabolic pathways,⁴⁶ is a fundamental precursor of glutathione. Under fasting or 313 314 starvation, glutamine serves gluconeogenesis, helping the liver to maintain blood glucose levels following glycogen-store shortages.⁴⁷ In rats, glutamine supplementation protects against STZ-315 induced renal injury and prevents downregulation of the kidney injury molecule-1 (KIM-1), 316 neutrophil gelatinase-associated lipocalin (NGAL), TGF-β1, and collagen-1 mRNA expressions.⁴⁸ 317 In diabetic patients, glutamine supplementation decreases glycemia through increased glucagon-318 like peptide 1 (GLP-1) secretion.⁴⁹ By presenting lower glutamine concentrations, H10 carriers 319 might have more difficulty in rebalancing glucose metabolism in the event of glucose deficiency. 320 321 The absence of associations of H3 and H10 with clinical traits limits further interpretation.

We modeled haplotypes within two recombination hotspots at positions 76,251,700 and 322 76.516.500 on chromosome 4g21.1 that clearly delineate the genetic locus associated with eGFR 323 in all GWAS reported so far. Prokop et al.¹⁰ showed that variants within those two peaks are in LD 324 with variants outside the peaks such as SHROOM3 P1244L, located downstream the second 325 peak and associated with high CKD risk in Eastern Asia.¹⁰ They also observed that the locus is 326 associated with TCF7L2, a chromosome 10 transcriptional factor with a broad phenotypic 327 spectrum.⁵⁰ Our annotation analyses extend these observations, showing that several haplotype-328 tagging variants are also associated with proteins (NAR3, CXCL11, and NAAA) whose encoding 329 330 genes are located immediately upstream the recombination hotspot adjacent to FAM47E, 331 between chromosome 4 positions 75,910,655 and 76,114,048. These associations might reflect underlying longer haplotypes spanning those genes as well. NAR3 is encoded by ART3, which is 332 specifically expressed in the mesangium of the glomerulus.⁵¹ It warrants further investigation 333 whether joint involvement of SHROOM3 on podocytes and ART3 on the mesangium is possible 334 335 and if that might implicate relevant kidney phenotypes. CXCL11 is a proinflammatory chemokine implicated in kidney disease induced by interferon signaling.⁵² Urine CXCL11 correlates with 336 diabetic kidney disease progression⁵³ and is upregulated in the glomeruli of nephrotic syndrome 337 patients carrying APOL1 high risk variants.⁵⁴ In mice with acute glomerular inflammation, genetic 338 deletion of CXCL11 receptor Cxcr3 attenuates glomerulosclerosis and albuminuria.⁵⁵ NAAA is a 339 proinflammatory protein emerging as a promising target in mouse models of parkinsonism,⁵⁶ 340 without evident links to kidney function. Other associated proteins, encoded by genes in other 341 chromosomes (SMPD1, HYAL1, ATF6B, and CXCL6), may reflect either FAM47E transcriptional 342 activity or biological consequences of the proteins encoded by the genes tagged by the 343 344 haplotypes.

345 The main strength of our analysis was the availability of WES data from a subsample 346 which we used to impute exonic variants in the whole study sample of >12,000 individuals, enabling the reconstruction of haplotypes with frequencies as low as 2% in the population across 347 348 clinical traits, metabolites, and proteins. Limitations are also present. The proteomics panel included mostly highly abundant plasma proteins, none of which resulted associated with 349 haplotypes at this locus. The successful single-variant query of external proteomic datasets 350 suggests that haplotype associations with those same proteins might be identified should 351 352 individual-level data become available. Despite the large sample size, haplotypes are multicategory variables that easily generate data sparseness, eroding statistical power. Finally, 353 354 consistent with GWAS studies that identified significant associations with complex traits at this 355 locus, we focused our investigation on the region bounded by the two recombination hotspots at 356 chromosome 4 positions 76,251,700 and 76,516,500: given most SHROOM3 exons fall outside 357 this segment, this constraint has probably limited the possibility to contextualize SHROOM3 with 358 the other genes. On the other hand, extrapolating haplotypes at arbitrary distance outside the 359 borders would have increased data sparseness.

In conclusion, our investigation revealed the presence of distinct genetic profiles at
 FAM47E-SHROOM3 associated with heterogeneous phenotypic and metabolic combinations that
 warrant dedicated investigation.

363

364 Ethics approval and consent to participate

The Ethics Committee of the Healthcare System of the Autonomous Province of Bolzano-South Tyrol approved the CHRIS baseline protocol on 19 April 2011 (21-2011). The study conforms to the Declaration of Helsinki, and with national and institutional legal and ethical requirements. All participants included in the analysis gave written informed consent.

369

370 Acknowledgements

The CHRIS study is conducted in collaboration between the Eurac Research Institute for Biomedicine and the Healthcare System of the Autonomous Province of Bolzano-South Tyrol. Investigators thank all study participants, the general practitioners of the Val Venosta/ Vinschgau district, and the staff of the Silandro/Schlanders hospital and of the Autonomous Province of Bolzano-South Tyrol Healthcare System for their support and collaboration. They also thank the study team in Silandro/Schlanders, the CHRIS Biobank personnel, and all Institute for

377 Biomedicine colleagues who contributed to the study. Extensive acknowledgement is reported at:

378 https://www.eurac.edu/en/institutes-centers/institute-for-biomedicine/pages/acknowledgements.

379 CHRIS Bioresource Research Impact Factor (BRIF) code: BRIF6107. The authors thank the

380 Department of Innovation, Research and University of the Autonomous Province of Bolzano-

- 381 South Tyrol for covering the Open Access publication costs.
- 382

383 Funding

- The CHRIS study was funded by the Department of Innovation, Research and University of the Autonomous Province of Bolzano-South Tyrol and supported by the European Regional Development Fund (FESR1157). This work was carried out within the TrainCKDis project, funded by the European Union's Horizon 2020 research and innovation programme under the Marie
- 388 Skłodowska-Curie grant agreement H2020-MSCA-ITN-2019 ID:860977 (TrainCKDis).
- 389

390 Author contributions

- 391 Conceptualization of the research project: C.P., D.G.
- 392 Recruitment and study management: M.G., P.P.P., C.P.
- 393 Bioinformatics: D.G., E.K., N.D.
- 394 Data quality control and harmonization: M.G., J.R., M.R., L.F.
- 395 Statistical Analysis: D.G.
- 396 Results interpretation: D.G., C.P., M.G., L.F., D.A.
- 397 Manuscript drafting: D.G., C.P.
- 398 Manuscript critical revision: All authors
- 399

400 **Competing interests**

- 401 CP is consultant for Quotient Therapeutics. DA is employed by AstraZeneca. The other authors
- 402 declare no competing financial interests.
- 403
- 404 Data availability

405 The data used in the current study can be requested with an application to 406 <u>access.request.biomedicine@eurac.edu</u> at the Eurac Research Institute for Biomedicine. **Table 1**. Main characteristics of the study sample. Data are described as median (interquartile range) or number of cases (percentage), as appropriate. Additional characteristics are described in Supplementary Table 1.

Participants' characteristics	Group of traits and sample size			
	Clinical traits (n=12,834)	Metabolites (n=6,642)	Proteins (n=3,535)	
Age, years	46 (31 – 57)	46 (32 – 58)	46 (32 – 58)	
Females	6,969 (54.3%)	3,650 (55.0%)	1,977 (55.9%)	
eGFRcrea, ml/min/1.73 m ²	92.9 (81.7 – 104.1)	92.2 (81.1 – 103.5)	92.2 (80.8 – 103.3)	
eGFRcrea < 60 ml/min/1.73 m ²	460 (3.6%)	269 (4.1%)	143 (4.1%)	
UACR > 30 mg/g	752 (5.9%)	393 (5.9%)	225 (6.4%)	
HbA1c > 6.5%	189 (1.5%)	97 (1.5%)	54 (1.5%)	
Hypertension*	2,023 (15.8%)	1,002 (15.1%)	536 (15.2%)	

* systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg

Group	Haplotype	Trait	Effect (SE)**	P-value
-	H1	SBP	0.054 (0.023)	0.017156
		MCH	-0.063 (0.027)	0.018654
		HGB	-0.044 (0.021)	0.037743
		Magnesium	-0.056 (0.027)	0.041443
		Basophils	-0.145 (0.041)	4.18E-04
	H4	Magnesium	-0.139 (0.041)	6.74E-04
		eGFRcrea	0.089 (0.029)	0.002221
		BMI	0.118 (0.039)	0.002364
		Serum creatinine	-0.094 (0.032)	0.003637
		UACR	0.085 (0.039)	0.027938
	H5	ALP	-0.101 (0.049)	0.039383
		Serum creatinine	-0.084 (0.018)	4.92E-06
	H6	eGFRcrea	0.048 (0.017)	0.003950
Clinical traits		PLT	-0.052 (0.023)	0.021181
		Magnesium	-0.106 (0.043)	0.014985
	H/	Serum creatinine	-0.069 (0.034)	0.043883
		eGFRcrea	0.113 (0.031)	2.72E-04
	H8	Serum creatinine	-0.111 (0.034)	0.001136
		UACR	0.122 (0.041)	0.003278
		SBP	0.084 (0.036)	0.019310
	H9	HGB	-0.069 (0.027)	0.010716
		RBC	-0.069 (0.030)	0.022546
		НСТ	-0.063 (0.028)	0.025566
		eGFRcrea	0.056 (0.025)	0.026760
		Magnesium	-0.075 (0.035)	0.032351
		Serum creatinine	-0.054 (0.028)	0.049913
	H10	Magnesium	-0.125 (0.040)	0.001810
Metabolites	H1	Phosphatidylcholine diacyl C42:0	0.134 (0.038)	4.39E-04
	H3	Histidine	-0.215 (0.061)	4.28E-04
	H6	Dodecenoylcarnitine	-0.116 (0.032)	2.82E-04
		Hydroxyvalerylcarnitine ***	-0.122 (0.032)	1.31E-04
		Tiglylcarnitine	-0.113 (0.032)	4.48E-04
	H10	Glutamine	-0.196 (0.051)	1.08E-04
		Putrescine	-0.195 (0.053)	2.26E-04

Table 2. Statistically significant* haplotype associations with blood, urine, anthropometric, and metabolic traits in the CHRIS study. No significant association was observed with proteins.

*Statistical significance was set at $\alpha = 0.05$ for traits with prior evidence of association and $\alpha = 0.05$ to the number of principal components explaining 95% of the set variability for traits and metabolites with no prior evidence of association (see Methods). **Effects are expressed in terms of standard deviations as all traits were normalized using the inverse-normal transformation (see Methods) ***Also known as Methylmalonylcarnitine

Table 3. Covariate-adjusted haplotype-metabolite association models. Association models between each haplotype and the associated metabolite (**Table 2**) were adjusted for the traits associated with the same haplotype to assess potential mediation.

Haplotype	Phenotype	Covariate	Effect (SE)	P-value
H1	Phosphatidylcholine diacyl C42:0	SBP	0.135 (0.038)	0.000340
		HGB	0.134 (0.038)	0.000437
		Magnesium	0.133 (0.038)	0.000458
- H6	Dodecenoylcarnitine	Serum creatinine	-0.097 (0.031)	0.001950
		eGFRcrea	-0.106 (0.032)	0.000792
		PLT	-0.117 (0.032)	0.000264
	Hydroxyvalerylcarnitine (Methylmalonylcarnitine)	Serum creatinine	-0.108 (0.032)	0.000645
		eGFRcrea	-0.114 (0.032)	0.000322
		PLT	-0.122 (0.032)	0.000129
	Tiglylcarnitine	Serum creatinine	-0.097 (0.032)	0.002170
		eGFRcrea	-0.103 (0.032)	0.001130
		PLT	-0.115 (0.032)	0.000336
H10	Glutamine	Magnesium	-0.197 (0.051)	0.000104
	Putrescine	Magnesium	-0.195 (0.053)	0.000239

Figure legends

Figure 1. Analysis setting. **Panel A.** Analysis flowchart. **Panel B.** Regional association plot depicting associations between variants in and around the *FAM47E-SHROOM3* locus in the CHRIS study, reflecting a similar association pattern as that identified by a recent CKDGen GWAS meta-analysis⁴: the most associated SNP in the CKDGen analysis is highlighted in purple. SNP positions are referred to the NCBI Build 38. Plot generated with LocusZoom v1.4⁵⁷.

Figure 2. Characteristics of the variants included in the FAM47E-SHROOM3 region on chromosome 4 (76,251,700-76,516,500 bp). Panel A. Minus log₁₀ P-values of the significant associations between any of the 146 variants used for haplotype reconstruction and 18 GWAS Catalog traits that are also present in the CHRIS study. Colors and shapes of the dots are used to distinguish the different genes the variants belong to. Traits: creatinine-based estimated glomerular filtration rate, eGFRcrea; serum creatinine, SCr; hematocrit, HCT; red blood cell count, RBC; hemoglobin, HGB; alanine transaminase, ALT GPT; height; serum albumin, SAlb; alkaline phosphatase, ALP; aspartate aminotransferase, AST GOT; triglycerides, TG; urine albumincreatinine ratio, UACR; serum magnesium; low-density lipoprotein (LDL) cholesterol; platelet count, PLT; mean corpuscular hemoglobin, MCH; systolic blood pressure, SBP; and body mass index, BMI. Panel B. Barplot of the most severe consequences of the 146 variants identified for haplotype reconstruction. Panel C. Linkage disequilibrium pattern of the FAM47E-SHROOM3 locus, based on the D' statistic. Included are variants associated with complex traits from previous genome-wide association studies and haplotype-tagging variants. The labels on x- and y-axis are annotated by the corresponding gene symbol and RSID. On the vertical axis, we also report the associated complex trait, as per GWAS Catalog interrogation. Variants' RSID color coding indicates: the most associated variant, rs28817415, with eGFRcrea ⁵ (orange); 25 of the 27 haplotype-tagging variants (two variants were not represented in the LD reference panel) (purple); and 31 variants for which there was a GWAS Catalog genome-wide significant association with a trait among those included in the CHRIS study (black). Panel D. Distribution of the 11 reconstructed haplotypes, identified by 27 tagging variants with their functional consequences given on the x-axis. Haplotype frequencies are reported right of the haplotype label for the three analyzed subsamples in the order: all individuals with clinical traits; those with also metabolites measurements; those with additional protein measurements.

Figure 3. Association of the 27 haplotype-tagging variants with gene expression and protein levels. **Panel A**: Normalized effect size of association between the 27 haplotype-tagging variants and expression of *FAM47E*, *STBD1*, and *CCDC158* (horizontal axis; genes grouped by variant) across 46 tissues (vertical axis) retrieved from the GTEx v8 dataset. Uterus and vagina tissues and *SHROOM3* were omitted for the lack of significant results. **Panel B**: Normalized effect size for association between the 27 haplotype-tagging variants (horizontal axis) and protein concentrations (vertical axis) retrieved from the deCODE dataset ³⁴. Listed are only proteins with a significant association with at least one variant.

Figure 4. Hierarchical cluster analysis of z-scores from the associations between haplotypes with any of the 13 clinical traits and 7 metabolites that were associated with at least one haplotype (indicated with *), in the subset of study participants with metabolites measurements available. Haplotype H5 was excluded as it did not reach the 2% frequency in this subsample.

References

1. Köttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. *Nat Genet*. Jun 2009;41(6):712-717. doi:10.1038/ng.377

2. Köttgen A, Pattaro C, Böger CA, et al. New loci associated with kidney function and chronic kidney disease. *Nat Genet*. May 2010;42(5):376-384. doi:10.1038/ng.568

3. Pattaro C, Köttgen A, Teumer A, et al. Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function. *PLOS Genetics*. 2012;8(3):e1002584. doi:10.1371/journal.pgen.1002584

4. Wuttke M, Li Y, Li M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nat Genet*. Jun 2019;51(6):957-972. doi:10.1038/s41588-019-0407-x

5. Stanzick KJ, Li Y, Schlosser P, et al. Discovery and prioritization of variants and genes for kidney function in >1.2 million individuals. *Nature Communications*. 2021/07/16 2021;12(1):4350. doi:10.1038/s41467-021-24491-0

6. Pattaro C, De Grandi A, Vitart V, et al. A meta-analysis of genome-wide data from five European isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level. *BMC Med Genet.* Mar 11 2010;11:41. doi:10.1186/1471-2350-11-41

7. Teumer A, Chaker L, Groeneweg S, et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. *Nature Communications*. 2018/10/26 2018;9(1):4455. doi:10.1038/s41467-018-06356-1

8. Hildebrand JD, Soriano P. Shroom, a PDZ domain-containing actin-binding protein, is required for neural tube morphogenesis in mice. *Cell.* Nov 24 1999;99(5):485-497. doi:10.1016/s0092-8674(00)81537-8

9. Yeo NC, O'Meara CC, Bonomo JA, et al. Shroom3 contributes to the maintenance of the glomerular filtration barrier integrity. *Genome Res.* Jan 2015;25(1):57-65. doi:10.1101/gr.182881.114

10. Prokop JW, Yeo NC, Ottmann C, et al. Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD. *J Am Soc Nephrol.* May 2018;29(5):1525-1535. doi:10.1681/asn.2017080856

11. Khalili H, Sull A, Sarin S, et al. Developmental Origins for Kidney Disease Due to Shroom3 Deficiency. *J Am Soc Nephrol*. Oct 2016;27(10):2965-2973. doi:10.1681/asn.2015060621

12. Matsuura R, Hiraishi A, Holzman LB, et al. SHROOM3, the gene associated with chronic kidney disease, affects the podocyte structure. *Scientific Reports*. 2020/12/03 2020;10(1):21103. doi:10.1038/s41598-020-77952-9

13. Lemay P, Guyot MC, Tremblay É, et al. Loss-of-function de novo mutations play an important role in severe human neural tube defects. *J Med Genet*. Jul 2015;52(7):493-497. doi:10.1136/jmedgenet-2015-103027

14. Deshwar AR, Martin N, Shannon P, Chitayat D. A homozygous pathogenic variant in SHROOM3 associated with anencephaly and cleft lip and palate. *Clin Genet*. Sep 2020;98(3):299-302. doi:10.1111/cge.13804

15. Durbin MD, O'Kane J, Lorentz S, Firulli AB, Ware SM. SHROOM3 is downstream of the planar cell polarity pathway and loss-of-function results in congenital heart defects. *Dev Biol.* Aug 15 2020;464(2):124-136. doi:10.1016/j.ydbio.2020.05.013

16. Chen MH, Raffield LM, Mousas A, et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. *Cell.* Sep 3 2020;182(5):1198-1213.e1114. doi:10.1016/j.cell.2020.06.045

17. Meyer TE, Verwoert GC, Hwang SJ, et al. Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. *PLoS Genet*. Aug 5 2010;6(8)doi:10.1371/journal.pgen.1001045

18. Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet*. Oct 2017;49(10):1511-1516. doi:10.1038/ng.3955

19. Wei C, Banu K, Garzon F, et al. SHROOM3-FYN Interaction Regulates Nephrin Phosphorylation and Affects Albuminuria in Allografts. *J Am Soc Nephrol.* Nov 2018;29(11):2641-2657. doi:10.1681/asn.2018060573

20. Ghasemi-Semeskandeh D, Emmert D, König E, et al. Systematic mediation and interaction analyses in an individual population study help characterize kidney function genetic loci. *medRxiv*. 2023:2023.2004.2015.23288540. doi:10.1101/2023.04.15.23288540

21. Pattaro C, Gögele M, Mascalzoni D, et al. The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results. *Journal of Translational Medicine*. 2015/11/05 2015;13(1):348. doi:10.1186/s12967-015-0704-9

22. Arisido MW, Foco L, Shoemaker R, et al. Cluster analysis of angiotensin biomarkers to identify antihypertensive drug treatment in population studies. *BMC Med Res Methodol*. May 27 2023;23(1):131. doi:10.1186/s12874-023-01930-8

23. König E, Rainer J, Hernandes VV, et al. Whole Exome Sequencing Enhanced Imputation Identifies 85 Metabolite Associations in the Alpine CHRIS Cohort. *Metabolites*. 2022;12(7):604.

24. Emmert DB, Vukovic V, Dordevic N, et al. Genetic and Metabolic Determinants of Atrial Fibrillation in a General Population Sample: The CHRIS Study. *Biomolecules*. 2021;11(11):1663. 25. Pattaro C, Riegler P, Stifter G, Modenese M, Minelli C, Pramstaller PP. Estimating the glomerular filtration rate in the general population using different equations: effects on classification and association. *Nephron Clin Pract*. 2013;123(1-2):102-111. doi:10.1159/000351043

26. Noce D, Gögele M, Schwienbacher C, et al. Sequential recruitment of study participants may inflate genetic heritability estimates. *Hum Genet*. Jun 2017;136(6):743-757. doi:10.1007/s00439-017-1785-8

27. Verri Hernandes V, Dordevic N, Hantikainen EM, et al. Age, Sex, Body Mass Index, Diet and Menopause Related Metabolites in a Large Homogeneous Alpine Cohort. *Metabolites*. 2022;12(3):205.

28. Messner CB, Demichev V, Bloomfield N, et al. Ultra-fast proteomics with Scanning SWATH. *Nat Biotechnol*. Jul 2021;39(7):846-854. doi:10.1038/s41587-021-00860-4

29. Dordevic N, Dierks C, Hantikainen E, et al. Pervasive Influence of Hormonal Contraceptives on the Human Plasma Proteome in a Broad Population Study. *medRxiv*. 2023:2023.2010.2011.23296871. doi:10.1101/2023.10.11.23296871

30. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score Tests for Association between Traits and Haplotypes when Linkage Phase Is Ambiguous. *The American Journal of Human Genetics*. 2002/02/01/ 2002;70(2):425-434. doi:<u>https://doi.org/10.1086/338688</u> 31. Lewontin RC. On measures of gametic disequilibrium. *Genetics*. Nov 1988;120(3):849-852. doi:10.1093/genetics/120.3.849

32. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*. 2015;4(1)doi:10.1186/s13742-015-0047-8

33. Han SK, McNulty MT, Benway CJ, et al. Mapping genomic regulation of kidney disease and traits through high-resolution and interpretable eQTLs. *Nat Commun.* Apr 19 2023;14(1):2229. doi:10.1038/s41467-023-37691-7

34. Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma proteome with genetics and disease. *Nat Genet*. Dec 2021;53(12):1712-1721. doi:10.1038/s41588-021-00978-w

35. Wang TJ, Evans JC, Meigs JB, et al. Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression. *Circulation*. 2005;111(11):1370-1376. doi:doi:10.1161/01.CIR.0000158434.69180.2D

36. Indiveri C, Iacobazzi V, Tonazzi A, et al. The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology. *Molecular Aspects of Medicine*. 2011/08/01/2011;32(4):223-233. doi:<u>https://doi.org/10.1016/j.mam.2011.10.008</u>

37. Goek O-N, Döring A, Gieger C, et al. Serum Metabolite Concentrations and Decreased GFR in the General Population. *American Journal of Kidney Diseases*. 2012/08/01/2012;60(2):197-206. doi:<u>https://doi.org/10.1053/j.ajkd.2012.01.014</u>

38. Fouque D, Holt S, Guebre-Egziabher F, et al. Relationship Between Serum Carnitine, Acylcarnitines, and Renal Function in Patients With Chronic Renal Disease. *Journal of Renal Nutrition*. 2006/04/01/2006;16(2):125-131. doi:<u>https://doi.org/10.1053/j.jrn.2006.01.004</u>

39. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. *Kidney international*. 2006;70(2):246-250.

40. Watanabe M, Suliman ME, Qureshi AR, et al. Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. *Am J Clin Nutr.* 2008/06// 2008;87(6):1860-1866. doi:10.1093/ajcn/87.6.1860

41. Vera-Aviles M, Vantana E, Kardinasari E, Koh NL, Latunde-Dada GO. Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. *Pharmaceuticals*. 2018;11(4):111.

42. Sieckmann T, Schley G, Ögel N, et al. Strikingly conserved gene expression changes of polyamine regulating enzymes among various forms of acute and chronic kidney injury. *Kidney Int.* Jul 2023;104(1):90-107. doi:10.1016/j.kint.2023.04.005

43. Saito A, Takagi T, Chung TG, Ohta K. Serum levels of polyamines in patients with chronic renal failure. *Kidney Int Suppl.* Dec 1983;16:S234-237.

44. Luo Q, Liang W, Zhang Z, et al. Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism. *Metabolism*. Sep 2022;134:155245. doi:10.1016/j.metabol.2022.155245

45. Yasuda-Yamahara M, Kume S, Maegawa H. Roles of mTOR in Diabetic Kidney Disease. *Antioxidants (Basel)*. Feb 22 2021;10(2)doi:10.3390/antiox10020321

46. Stumvoll M, Perriello G, Meyer C, Gerich J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. *Kidney International*. 1999/03/01/ 1999;55(3):778-792. doi:<u>https://doi.org/10.1046/j.1523-1755.1999.055003778.x</u>

47. Miller RA, Shi Y, Lu W, et al. Targeting hepatic glutaminase activity to ameliorate hyperglycemia. *Nat Med.* May 2018;24(4):518-524. doi:10.1038/nm.4514

48. Sadar S, Kaspate D, Vyawahare N. Protective effect of L-glutamine against diabetesinduced nephropathy in experimental animal: Role of KIM-1, NGAL, TGF-β1, and collagen-1. *Ren Fail.* Oct 2016;38(9):1483-1495. doi:10.1080/0886022x.2016.1227918

49. Samocha-Bonet D, Chisholm DJ, Gribble FM, et al. Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. *PLoS One*. 2014;9(11):e113366. doi:10.1371/journal.pone.0113366

50. Del Bosque-Plata L, Hernández-Cortés EP, Gragnoli C. The broad pathogenetic role of TCF7L2 in human diseases beyond type 2 diabetes. *J Cell Physiol*. Jan 2022;237(1):301-312. doi:10.1002/jcp.30581

51. Chung JJ, Goldstein L, Chen YJ, et al. Single-Cell Transcriptome Profiling of the Kidney Glomerulus Identifies Key Cell Types and Reactions to Injury. *J Am Soc Nephrol.* Oct 2020;31(10):2341-2354. doi:10.1681/asn.2020020220

52. Antonelli A, Ferrari SM, Mancusi C, et al. Interferon- α , - β and - γ induce CXCL11 secretion in human thyrocytes: Modulation by peroxisome proliferator-activated receptor γ agonists. *Immunobiology*. 2013/05/01/ 2013;218(5):690-695. doi:https://doi.org/10.1016/j.imbio.2012.08.267

53. Lebherz-Eichinger D, Klaus DA, Reiter T, et al. Increased chemokine excretion in patients suffering from chronic kidney disease. *Translational Research*. 2014/12/01/ 2014;164(6):433-443.e432. doi:https://doi.org/10.1016/j.trsl.2014.07.004

54. Sampson MG, Robertson CC, Martini S, et al. Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects. *Journal of the American Society of Nephrology*. 2016;27(3)

55. Panzer U, Steinmetz OM, Paust H-J, et al. Chemokine Receptor CXCR3 Mediates T Cell Recruitment and Tissue Injury in Nephrotoxic Nephritis in Mice. *Journal of the American Society of Nephrology*. 2007;18(7):2071-2084. doi:10.1681/asn.2006111237

56. Palese F, Pontis S, Realini N, et al. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. *Pharmacol Res.* Aug 2022;182:106338. doi:10.1016/j.phrs.2022.106338

57. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010;26(18):2336-2337. doi:10.1093/bioinformatics/btq419







Figure 3.





Figure 4.

Supplementary materials

Supplementary Methods

Haplotypes were reconstructed using the expectation-maximization algorithm implemented in the R package 'haplo.stats' v1.8.9 with the following parameter setting: n.try=2 (number of times to try to maximize the log-likelihood); insert.batch.size=2 (number of loci to be inserted in a single batch); max.haps.limit=4e6 (maximum number of haplotypes for the input genotypes); and min.posterior=1e-5 (minimum posterior probability for a haplotype pair, given the input genotypes).

Supplementary Figure 1. Interrogation of the 146 variants in association with any complex trait in the GWAS Catalog. Minus log₁₀ P-values of the significant associations are presented. Only genome-wide significant associations (P-value<5×10⁻⁸) are presented. Colors and shapes of the dots are used to distinguish the different genes to which the variants belong.



Supplementary Figure 2. Haplotypes reconstructed based on the 146 available WES-imputed variants. On top, variants are listed by gene name – chromosomal position – alleles. At the bottom, variants' functional consequences. Middle panel: the most common, reference haplotype is provided in its entirety (first line). Other haplotypes are presented by listing only the alleles that are different from the reference haplotype. When the allele is the same as in the reference haplotype, the letter is not displayed.



Supplemental Figure 3. Haplotype association analysis results. Displayed are the effect coefficients and their 95% confidence intervals from the associations between haplotypes with the 13 clinical traits and 7 metabolites that were associated with at least one haplotype, in the subset of participants with metabolites measurements available. Haplotype 5 (H5) was excluded as it did not reach the 2% frequency in this subsample.



Haplotype effect on clinical traits and metabolites

Supplemental Figure 4. Cluster analysis of the standardized effects of haplotypes on significant clinical traits and metabolites. **Panel A.** Results of the Silhouette method applied to the clustering of haplotypes: the number of clusters (x-axis) is plotted against the average silhouette width (y-axis). **Panel B.** Results of the Silhouette method applied to the clustering of traits: the number of clusters (x-axis) is plotted against the average silhouette width (y-axis) is plotted against the average silhouette width (y-axis) is plotted against the average silhouette width (y-axis). **Panel C.** Hierarchical clustering of haplotypes (listed and clustered on the y-axis). **Panel D.** Hierarchical clustering of clinical traits and metabolites (listed and clustered on the y-axis). Colors are used to identify the clusters.

